<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nid</journal-id><journal-title-group><journal-title xml:lang="ru">Нефрология и диализ</journal-title><trans-title-group xml:lang="en"><trans-title>Nephrology and Dialysis</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1680-4422</issn><issn pub-type="epub">2618-9801</issn><publisher><publisher-name>Российское диализное общество</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.28996/2618-9801-2019-4-419-429</article-id><article-id custom-type="elpub" pub-id-type="custom">nid-307</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ШКОЛА НЕФРОЛОГА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>EDUCATIONAL MATERIALS</subject></subj-group></article-categories><title-group><article-title>«Подводные камни» статистического анализа и клинической интерпретации полученных оценок на примере пациентов с хронической болезнью почек. Часть I: Оценка риска</article-title><trans-title-group xml:lang="en"><trans-title>Pitfalls of statistical analysis and clinical interpretation of the estimates in patients with chronic kidney disease. Part I: Risk assessment</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зулькарнаев</surname><given-names>А. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Zulkarnaev</surname><given-names>A. B.</given-names></name></name-alternatives><email xlink:type="simple">7059899@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Хирургическое отделение трансплантологии и диализа, ГБУЗ МО Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Surgical Department of Transplantology and dialysis, M.F. Vladimirsky Moscow Regional Research Clinical Institute</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>07</day><month>08</month><year>2024</year></pub-date><volume>21</volume><issue>4</issue><fpage>419</fpage><lpage>429</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Зулькарнаев А.Б., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Зулькарнаев А.Б.</copyright-holder><copyright-holder xml:lang="en">Zulkarnaev A.B.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nephro.ru/jour/article/view/307">https://journal.nephro.ru/jour/article/view/307</self-uri><abstract><p>Отношение рисков (ОР) и отношение шансов (ОШ) - широко распространенные методы оценки сопряженности фактора риска и исхода. ОШ является косвенным выражением ОР и позволяет судить о полярности изменения абсолютного риска и его статистической значимости, но часто дает искаженное представление о кратности изменения риска под воздействием анализируемого фактора (как правило, ОШ "переоценивает" ОР). В случае маргинальной частоты исходов менее 10% оценка ОШ очень близка к ОР. Поэтому нередко при проведении мета-анализов, посвященных факторам риска редких заболеваний, за ОР принимают ОШ, в иных случаях оценка ОР может быть получена из ОШ при наличии точных данных о распространённости заболевания или риске в неэкспонированной группе. Несмотря на то, что ОР более наглядно, наиболее часто для оценки связи фактора риска и исхода используют ОШ. Этому есть несколько объяснений. ОШ универсально: в отличие от ОР, ОШ можно оценить не только при когортном исследовании, но и исследовании "случай-контроль". ОШ значительно удобнее, поскольку позволяет получить обратные оценки не только по отношению к фактору риска, но и по отношению к исходу. Однофакторный анализ, не учитывающий влияние различных вмешивающихся факторов (которые не являются непосредственной целью анализа) может приводить к смещенной оценке (примером может служить парадокс Симпсона). Чтобы преодолеть эту проблему, применяют многофакторный анализ. Одним из наиболее часто применяемых видов многофакторного анализа является логистическая регрессия. Как в случае когортных исследований, так и исследований "случай-контроль" в исходе применения этого метода связь факторов риска и исходов оценивается при помощи выражения ОШ. В статье представлен способ конверсии скорректированного ОШ в ОР (а также границ доверительного интервала) и приведены примеры. Следует помнить, что и ОР, и ОШ при непосредственной эмпирической оценке носят кумулятивный характер, не предполагают цензурированных наблюдений, не учитывают влияние ковариат и время наблюдения. Если субъекты исследования имеют разное время наблюдения, то связь фактора риска и исхода можно проанализировать путем вычисления интенсивности, с которой происходят события. Этот показатель известен как плотность инцидентности (заболеваемости) и представляет отношение количества событий к суммарному времени наблюдения пациентов. Отношение таких оценок в двух группах может быть интерпретировано как относительный риск. Получить скорректированное значение рисков для различных факторов можно при помощи регрессии Пуассона, в которой анализируется влияние предикторов на интенсивность наступления событий. Таким образом, несмотря на кажущуюся простоту оценок ОШ и ОР, каждая из них обладает особенностями интерпретации. Необходимо владеть базовыми знаниями об особенностях ОШ и ОР, чтобы адекватно и в полной мере овладеть информацией, приводимой в научных публикациях и использовать ее в клинической практике.</p></abstract><trans-abstract xml:lang="en"><p>The risk ratio (RR) and odds ratio (OR) are widespread methods of assessment of risk factor and outcome contingency. OR is an indirect evaluation of RR. It gives the representation polarity of absolute risk changes and its statistical significance, but often gives a distorted view of the risk multiplicity under the influence of the analyzed risk factor (as a rule, OR "overestimates" the RR). In a case of the marginal frequencies of outcomes less than 10% of the assessment of OR is very close to RR value. Therefore, often when conducting meta-analyzes of the risk factors for rare diseases, the OR is taken for OR, in other cases, the RR can be estimated from the OR with accurate data on the disease prevalence or the risk in the unexposed group. Although the RR is more obvious, the OR is most often used to assess the relationship of the risk factor and outcome. There are several explanations for this. OR is universal: unlike RR, OR can be assessed not only in a cohort study, but also in a case-control study. OR is much more convenient because it allows one to get inverse estimates not only concerning the risk factor, but also concerning the outcome. Univariate analysis, which does not take into account the influence of various confounders (factors which are not the direct purpose of the analysis), can lead to a biased assessment (an example is the Simpson paradox). To overcome this problem, multivariate analysis is used. One of the most commonly used types of multivariate analysis is logistic regression. As in the case of cohort studies, and case-control studies the relationship between risk factors and outcomes is assessed using the expression OR. The article presents a method for converting adjusted OR to RR (as well as the limits of the confidence interval) and provides examples. It should be remembered that both RR and OR, with a direct empirical assessment, are cumulative, do not imply censored observations, do not take into account the influence of covariates and the time of observation. If the subjects of the study have different observation times, the relationship between the risk factor and the outcome can be analyzed by calculating the intensity of events. This indicator is known as incidence density and represents the ratio of the number of events to the total time of observation of patients. The ratio of such assessments in the two groups can be interpreted as relative risk. The adjusted risk value for various factors can be obtained using the Poisson regression, which analyzes the influence of predictors on the intensity of the occurrence of events. Thus, despite the seeming simplicity of the OR and RR estimates, each of them has features of interpretation. It is necessary to possess basic knowledge about the OR and RR features to adequately and fully understand the information given in scientific publications and use it in clinical practice.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>отношение шансов</kwd><kwd>отношение рисков</kwd><kwd>распространенность заболевания</kwd><kwd>инцидентность</kwd><kwd>плотность инцидентности</kwd><kwd>логистическая регрессия</kwd><kwd>оценка риска</kwd><kwd>статистика</kwd><kwd>odds ratio</kwd><kwd>risk ratio</kwd><kwd>disease prevalence</kwd><kwd>incidence</kwd><kwd>incidence density</kwd><kwd>logistic regression</kwd><kwd>risk assessment</kwd><kwd>statistics</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Knol M.J., Duijnhoven R.G., Grobbee D.E. et al. Potential misinterpretation of treatment effects due to use of odds ratios and logistic regression in randomized controlled trials. PLoS One. 2011;6(6):e21248.</mixed-citation><mixed-citation xml:lang="en">Knol M.J., Duijnhoven R.G., Grobbee D.E. et al. Potential misinterpretation of treatment effects due to use of odds ratios and logistic regression in randomized controlled trials. PLoS One. 2011;6(6):e21248.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Janani L., Mansournia M.A., Nourijeylani K. et al. Statistical Issues in Estimation of Adjusted Risk Ratio in Prospective Studies. Arch Iran Med. 2015 Oct;18(10):713-9. DOI: 0151810/AIM.0012.</mixed-citation><mixed-citation xml:lang="en">Janani L., Mansournia M.A., Nourijeylani K. et al. Statistical Issues in Estimation of Adjusted Risk Ratio in Prospective Studies. Arch Iran Med. 2015 Oct;18(10):713-9. DOI: 0151810/AIM.0012.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Nurminen M. To use or not to use the odds ratio in epidemiologic analyses? Eur J Epidemiol. 1995;11(4):365-71.</mixed-citation><mixed-citation xml:lang="en">Nurminen M. To use or not to use the odds ratio in epidemiologic analyses? Eur J Epidemiol. 1995;11(4):365-71.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">McNutt L.A., Wu C., Xue X. et al. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol. 2003;157(10):940-3.</mixed-citation><mixed-citation xml:lang="en">McNutt L.A., Wu C., Xue X. et al. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol. 2003;157(10):940-3.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Guyatt G.H., Oxman A.D., Santesso N. et al. Grade guidelines 12. Preparing summary of findings tables?binary outcomes. J Clin Epidemiol 2012; 69: 158-172.</mixed-citation><mixed-citation xml:lang="en">Guyatt G.H., Oxman A.D., Santesso N. et al. Grade guidelines 12. Preparing summary of findings tables?binary outcomes. J Clin Epidemiol 2012; 69: 158-172.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Deeks J.J., Higgins J.P.T., Altman D.G. Cochrane handbook for systematic reviews of interventions. Chapter 9: Analysing data and undertaking meta-analyses. The Cochrane Collaboration; 2011.</mixed-citation><mixed-citation xml:lang="en">Deeks J.J., Higgins J.P.T., Altman D.G. Cochrane handbook for systematic reviews of interventions. Chapter 9: Analysing data and undertaking meta-analyses. The Cochrane Collaboration; 2011.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Balasubramanian H., Ananthan A., Rao S. et al. Odds ratio vs risk ratio in randomized controlled trials. Postgrad Med. 2015; 127(4):359-67. DOI: 10.1080/00325481.2015.1022494.</mixed-citation><mixed-citation xml:lang="en">Balasubramanian H., Ananthan A., Rao S. et al. Odds ratio vs risk ratio in randomized controlled trials. Postgrad Med. 2015; 127(4):359-67. DOI: 10.1080/00325481.2015.1022494.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Shrier I., Steele R. Understanding the relationship between risks and odds ratios. Clin J Sport Med. 2006; 16(2):107-10.</mixed-citation><mixed-citation xml:lang="en">Shrier I., Steele R. Understanding the relationship between risks and odds ratios. Clin J Sport Med. 2006; 16(2):107-10.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Рубанович А.В., Хромов-Борисов Н.Н. Теоретический анализ показателей предсказательной эффективности бинарных генетических тестов. Экологическая генетика. 2013; 11(1): 77-90.</mixed-citation><mixed-citation xml:lang="en">Рубанович А.В., Хромов-Борисов Н.Н. Теоретический анализ показателей предсказательной эффективности бинарных генетических тестов. Экологическая генетика. 2013; 11(1): 77-90.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Huang P.P., Shu D.H., Su Z. et al. Association between lifestyle, gender and risk for developing end-stage renal failure in IgA nephropathy: a case-control study within 10 years. Ren Fail. 2019;41(1):914-920. DOI: 10.1080/0886022X.2019.1635029.</mixed-citation><mixed-citation xml:lang="en">Huang P.P., Shu D.H., Su Z. et al. Association between lifestyle, gender and risk for developing end-stage renal failure in IgA nephropathy: a case-control study within 10 years. Ren Fail. 2019;41(1):914-920. DOI: 10.1080/0886022X.2019.1635029.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">The portal for rare diseases and orphan drugs. [Internet] https://www.orpha.net/</mixed-citation><mixed-citation xml:lang="en">The portal for rare diseases and orphan drugs. [Internet] https://www.orpha.net/</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">IDF Diabetes Atlas - ed 8 (Database on the Internet) 2017. [Internet] http://www.idf.org/</mixed-citation><mixed-citation xml:lang="en">IDF Diabetes Atlas - ed 8 (Database on the Internet) 2017. [Internet] http://www.idf.org/</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Emerging Risk Factors Collaboration, Sarwar N., Gao P. et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010; 375(9733):2215-22. DOI: 10.1016/S0140-6736(10)60484-9.</mixed-citation><mixed-citation xml:lang="en">Emerging Risk Factors Collaboration, Sarwar N., Gao P. et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010; 375(9733):2215-22. DOI: 10.1016/S0140-6736(10)60484-9.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Зулькарнаев А.Б., Фоминых Н.М., Карданахишвили З.Б. Сосудистый доступ и выживаемость пациентов на гемодиализе: особенности причинно-следственной связи. Вестник трансплантологии и искусственных органов. 2019;21(2):49-58. DOI: 10.15825/1995-1191-2019-2-49-58.</mixed-citation><mixed-citation xml:lang="en">Зулькарнаев А.Б., Фоминых Н.М., Карданахишвили З.Б. Сосудистый доступ и выживаемость пациентов на гемодиализе: особенности причинно-следственной связи. Вестник трансплантологии и искусственных органов. 2019;21(2):49-58. DOI: 10.15825/1995-1191-2019-2-49-58.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Бикбов Б.Т., Томилина Н.А. Заместительная терапия терминальной хронической почечной недостаточности в Российской Федерации в 1998-2013 гг. Отчет по данным общероссийского регистра заместительной почечной терапии Российского диализного общества. Часть первая. Нефрология и диализ. 2015; 17(3, приложение): 5-111. DOI: 10.28996/1680-4422-2017-4suppl-1-95.</mixed-citation><mixed-citation xml:lang="en">Бикбов Б.Т., Томилина Н.А. Заместительная терапия терминальной хронической почечной недостаточности в Российской Федерации в 1998-2013 гг. Отчет по данным общероссийского регистра заместительной почечной терапии Российского диализного общества. Часть первая. Нефрология и диализ. 2015; 17(3, приложение): 5-111. DOI: 10.28996/1680-4422-2017-4suppl-1-95.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2015. 2017; [Internet] https://www.era-edta-reg.org/files/annualreports/pdf/AnnRep2015.pdf</mixed-citation><mixed-citation xml:lang="en">European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2015. 2017; [Internet] https://www.era-edta-reg.org/files/annualreports/pdf/AnnRep2015.pdf</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">United States Renal Data System. 2016 USRDS annual data report. Volume 2 - End-stage Renal Disease (ESRD) in the United States: 1 • Incidence, Prevalence, Patient Characteristics, and Treatment Modalities 2016; [Internet] https://www.usrds.org/2016/view/Default.aspx</mixed-citation><mixed-citation xml:lang="en">United States Renal Data System. 2016 USRDS annual data report. Volume 2 - End-stage Renal Disease (ESRD) in the United States: 1 • Incidence, Prevalence, Patient Characteristics, and Treatment Modalities 2016; [Internet] https://www.usrds.org/2016/view/Default.aspx</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang J., Yu K.F. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280(19):1690-1.</mixed-citation><mixed-citation xml:lang="en">Zhang J., Yu K.F. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280(19):1690-1.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Buraczynska M., Zukowski P., Wacinski P. et al. Chemotactic cytokine receptor 5 gene polymorphism: relevance to microvascular complications in type 2 diabetes. Cytokine. 2012 May;58(2):213-7. DOI: 10.1016/j.cyto.2012.01.007.</mixed-citation><mixed-citation xml:lang="en">Buraczynska M., Zukowski P., Wacinski P. et al. Chemotactic cytokine receptor 5 gene polymorphism: relevance to microvascular complications in type 2 diabetes. Cytokine. 2012 May;58(2):213-7. DOI: 10.1016/j.cyto.2012.01.007.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Parving H.H., Lewis J.B., Ravid M. et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int. 2006; 69(11):2057-63.</mixed-citation><mixed-citation xml:lang="en">Parving H.H., Lewis J.B., Ravid M. et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int. 2006; 69(11):2057-63.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Grant R.L. Converting an odds ratio to a range of plausible relative risks for better communication of research findings. BMJ. 2014;348:f7450. DOI: 10.1136/bmj.f7450.</mixed-citation><mixed-citation xml:lang="en">Grant R.L. Converting an odds ratio to a range of plausible relative risks for better communication of research findings. BMJ. 2014;348:f7450. DOI: 10.1136/bmj.f7450.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Sanghavi K., Brundage R.C., Miller M.B. et al. Genotype-guided tacrolimus dosing in African-American kidney transplant recipients. Pharmacogenomics J. 2017; 17(1):61-68. DOI: 10.1038/tpj.2015.87.</mixed-citation><mixed-citation xml:lang="en">Sanghavi K., Brundage R.C., Miller M.B. et al. Genotype-guided tacrolimus dosing in African-American kidney transplant recipients. Pharmacogenomics J. 2017; 17(1):61-68. DOI: 10.1038/tpj.2015.87.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Jacobson P.A., Schladt D., Oetting W.S. et al. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. Am J Transplant. 2012;12(12):3326-36. DOI: 10.1111/j.1600-6143.2012.04232.x.</mixed-citation><mixed-citation xml:lang="en">Jacobson P.A., Schladt D., Oetting W.S. et al. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. Am J Transplant. 2012;12(12):3326-36. DOI: 10.1111/j.1600-6143.2012.04232.x.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Peeters L.E.J., Andrews L.M., Hesselink D.A. et al. Personalized immunosuppression in elderly renal transplant recipients. Pharmacol Res. 2018;130:303-307. DOI: 10.1016/j.phrs.2018.02.031.</mixed-citation><mixed-citation xml:lang="en">Peeters L.E.J., Andrews L.M., Hesselink D.A. et al. Personalized immunosuppression in elderly renal transplant recipients. Pharmacol Res. 2018;130:303-307. DOI: 10.1016/j.phrs.2018.02.031.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Kievit R.A., Frankenhuis W.E., Waldorp L.J. et al. Simpson's paradox in psychological science: a practical guide. Front Psychol. 2013;4:513. DOI: 10.3389/fpsyg.2013.00513.</mixed-citation><mixed-citation xml:lang="en">Kievit R.A., Frankenhuis W.E., Waldorp L.J. et al. Simpson's paradox in psychological science: a practical guide. Front Psychol. 2013;4:513. DOI: 10.3389/fpsyg.2013.00513.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Hanley J.A., Th?riault G. Simpson's paradox in meta-analysis. Epidemiology. 2000;11(5):613-4.</mixed-citation><mixed-citation xml:lang="en">Hanley J.A., Th?riault G. Simpson's paradox in meta-analysis. Epidemiology. 2000;11(5):613-4.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Altman D.G., Deeks J.J. Meta-analysis, Simpson's paradox, and the number needed to treat. BMC Med Res Methodol. 2002;2:3.</mixed-citation><mixed-citation xml:lang="en">Altman D.G., Deeks J.J. Meta-analysis, Simpson's paradox, and the number needed to treat. BMC Med Res Methodol. 2002;2:3.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Gofrit O.N., Zorn K.C., Steinberg G.D. et al. The Will Rogers phenomenon in urological oncology. J Urol. 2008;179(1):28-33.</mixed-citation><mixed-citation xml:lang="en">Gofrit O.N., Zorn K.C., Steinberg G.D. et al. The Will Rogers phenomenon in urological oncology. J Urol. 2008;179(1):28-33.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Albertsen P.C., Hanley J.A., Barrows G.H. et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst. 2005;97(17):1248-53.</mixed-citation><mixed-citation xml:lang="en">Albertsen P.C., Hanley J.A., Barrows G.H. et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst. 2005;97(17):1248-53.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Wacholder S. Binomial regression in GLIM: estimating risk ratios and risk differences. Am J Epidemiol. 1986;123(1):174-84.</mixed-citation><mixed-citation xml:lang="en">Wacholder S. Binomial regression in GLIM: estimating risk ratios and risk differences. Am J Epidemiol. 1986;123(1):174-84.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Sangmuang P., Lucksiri A., Katip W. Factors Associated with Mortality in Immunocompetent Patients with Hospital-acquired Pneumonia. J Glob Infect Dis. 2019;11(1):13-18. DOI: 10.4103/jgid.jgid_33_18.</mixed-citation><mixed-citation xml:lang="en">Sangmuang P., Lucksiri A., Katip W. Factors Associated with Mortality in Immunocompetent Patients with Hospital-acquired Pneumonia. J Glob Infect Dis. 2019;11(1):13-18. DOI: 10.4103/jgid.jgid_33_18.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Park S.H., Jeong M.H., Park I.H. et al. Effects of combination therapy of statin and N-acetylcysteine for the prevention of contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Int J Cardiol. 2016;212:100-6. DOI: 10.1016/j.ijcard.2016.03.009.</mixed-citation><mixed-citation xml:lang="en">Park S.H., Jeong M.H., Park I.H. et al. Effects of combination therapy of statin and N-acetylcysteine for the prevention of contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Int J Cardiol. 2016;212:100-6. DOI: 10.1016/j.ijcard.2016.03.009.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Shah P.K., Yan P.L., Dauw C.A. et al. Emergency Department Switching and Duplicate Computed Tomography Scans in Patients With Kidney Stones. Urology. 2018;114:41-44. DOI: 10.1016/j.urology.2018.01.013.</mixed-citation><mixed-citation xml:lang="en">Shah P.K., Yan P.L., Dauw C.A. et al. Emergency Department Switching and Duplicate Computed Tomography Scans in Patients With Kidney Stones. Urology. 2018;114:41-44. DOI: 10.1016/j.urology.2018.01.013.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Muduma G., Odeyemi I., Smith-Palmer J. et al. Budget impact of switching from an immediate-release to a prolonged-release formulation of tacrolimus in renal transplant recipients in the UK based on differences in adherence. Patient Prefer Adherence. 2014;8:391-9. DOI: 10.2147/PPA.S60213.</mixed-citation><mixed-citation xml:lang="en">Muduma G., Odeyemi I., Smith-Palmer J. et al. Budget impact of switching from an immediate-release to a prolonged-release formulation of tacrolimus in renal transplant recipients in the UK based on differences in adherence. Patient Prefer Adherence. 2014;8:391-9. DOI: 10.2147/PPA.S60213.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Muduma G., Shaw J., Hart W.M. et al. Cost utility analysis of immunosuppressive regimens in adult renal transplant recipients in England and Wales. Patient Prefer Adherence. 2014;8:1537-46. DOI: 10.2147/PPA.S69461.</mixed-citation><mixed-citation xml:lang="en">Muduma G., Shaw J., Hart W.M. et al. Cost utility analysis of immunosuppressive regimens in adult renal transplant recipients in England and Wales. Patient Prefer Adherence. 2014;8:1537-46. DOI: 10.2147/PPA.S69461.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Yang Y., George K.C., Luo R. et al. Contrast-induced acute kidney injury and adverse clinical outcomes risk in acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis. BMC Nephrol. 2018;19(1):374. DOI: 10.1186/s12882-018-1161-5.</mixed-citation><mixed-citation xml:lang="en">Yang Y., George K.C., Luo R. et al. Contrast-induced acute kidney injury and adverse clinical outcomes risk in acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis. BMC Nephrol. 2018;19(1):374. DOI: 10.1186/s12882-018-1161-5.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Shang W., Li L., Ren Y. et al. History of kidney stones and risk of chronic kidney disease: a meta-analysis. PeerJ. 2017;5:e2907. DOI: 10.7717/peerj.2907.</mixed-citation><mixed-citation xml:lang="en">Shang W., Li L., Ren Y. et al. History of kidney stones and risk of chronic kidney disease: a meta-analysis. PeerJ. 2017;5:e2907. DOI: 10.7717/peerj.2907.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Crowley M.J., Diamantidis C.J., McDuffie J.R. et al. Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. Ann Intern Med. 2017;166(3):191-200. DOI: 10.7326/M16-1901.</mixed-citation><mixed-citation xml:lang="en">Crowley M.J., Diamantidis C.J., McDuffie J.R. et al. Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. Ann Intern Med. 2017;166(3):191-200. DOI: 10.7326/M16-1901.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Томилина Н.А., Андрусев А.М., Перегудова Н.Г. и соавт. Заместительная терапия терминальной хронической почечной недостаточности в Российской Федерации В 2010-2015 гг. Отчет по данным общероссийского регистра заместительной почечной терапии Российского диализного общества, часть первая. Нефрология и диализ. 2017; 19(4, приложение):1-95. DOI: 10.28996/1680-4422-2017-4suppl-1-95.</mixed-citation><mixed-citation xml:lang="en">Томилина Н.А., Андрусев А.М., Перегудова Н.Г. и соавт. Заместительная терапия терминальной хронической почечной недостаточности в Российской Федерации В 2010-2015 гг. Отчет по данным общероссийского регистра заместительной почечной терапии Российского диализного общества, часть первая. Нефрология и диализ. 2017; 19(4, приложение):1-95. DOI: 10.28996/1680-4422-2017-4suppl-1-95.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
